MGMT and glioblastoma: Treatment of the disease is largely ‘one size fits all’, even though GBM patients that are female, with methylated O6-methylguanine-DNA methyltransferase (MGMT) promoter, younger age, who underwent resection rather than biopsy and with pre-operative Karnofsky performance score ≥ 70 are associated with better outcome [33–37].